From: Update on the management of colchicine resistant Familial Mediterranean Fever (FMF)
Study | Description | Follow-up |
---|---|---|
Hashkes et al. [89] | 8 males and 6 females were randomly assigned to one of 4 treatment sequences that each included two 3-month courses of rilonacept by weekly subcutaneous injection, and two 3-month courses of placebo. | During the treatment periods with rilonacept, patients had fewer attacks of FMF than with placebo, and more patients had a decrease to less than 50% of their previous baseline number. Patients also reported better physical aspects of quality of life with rilonacept. Patients had pain with the rilonacept injections more often than with placebo. |
Hashkes et al. [90] | 14 FMF patients with their parents completed the modified Child Health Questionnaire at baseline, and at the start and end of each of 4 treatment courses, 2 each with rilonacept and placebo. | There were significant improvements in most health-related quality of life concepts after rilonacept but not placebo. Significant differences between rilonacept and placebo were found in the physical but not psychosocial scores. |
Sakallioglu et al. [91] | A case of a 15 year-old boy with polyarthritis while on colchicine treatment for FMF. His polyarthritis was resistant to treatment with prednisolone and methotrexate when etanercept was started. | He responded dramatically to etanercept and remained in full remission until 4 months when the drug was discontinued due to social and financial causes. |